-
11.发明授权公开(公告)号：US11026976B2
公开(公告)日：2021-06-08
申请号：US16664223
申请日：2019-10-25
Inventor： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Walter Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Guimaraes , Saar Gill , Marco Ruella , Regina M. Young
Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
12.发明授权公开(公告)号：US10889643B2
公开(公告)日：2021-01-12
申请号：US16069146
申请日：2017-01-11
Applicant: Novartis AG , Universität Zürich
Inventor： Natalia Arenas-Ramirez , Iwan Beuvink , Onur Boyman , Barbara Brannetti , Andreas Katopodis , Simone Popp , Catherine Regnier , Chao Zou
Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
-
公开(公告)号：US20200223917A1
公开(公告)日：2020-07-16
申请号：US16588063
申请日：2019-09-30
Inventor： Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu
IPC: C07K16/28 , G01N33/574 , A61K39/395 , A61K45/06 , G01N33/68
Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
-
公开(公告)号：US10253086B2
公开(公告)日：2019-04-09
申请号：US15094674
申请日：2016-04-08
Inventor： Hans Bitter , Jennifer Mary Bordeaux , Barbara Brannetti , Jennifer Brogdon , Naveen Kumar Dakappagari , Saar Gill , Steven Highfill , Lu Huang , Carl H. June , Ju Young Kim , Ming Lei , Na Li , Andreas Loew , Elena Orlando , Marco Ruella , Thai Tran , Jimin Zhang , Li Zhou
IPC: A61K38/00 , A61K39/00 , A61K45/06 , C07K16/28 , C07K14/705 , C07K14/725
Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
-
公开(公告)号：US20130295102A1
公开(公告)日：2013-11-07
申请号：US13716526
申请日：2012-12-17
Applicant: Novartis AG
Inventor： Leslie Ngozi Anuna Johnson , Ute Jaeger , Yong-In Kim , Christian Carsten Silvester Kunz , Igor Splawski , Michael Roguska , Joy Ghosh , Barbara Brannetti
IPC: C07K16/18 , G01N33/68 , C07K16/24 , A61K39/395
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/24 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/40 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6863
Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
-
Patent Agency Ranking
公开(公告)号：US20240252538A1
公开(公告)日：2024-08-01
申请号：US18529915
申请日：2023-12-05
Inventor： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Walter Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Patricia Pinto Guimaraes , Saar Gill , Marco Ruella , Regina M. Young
CPC classification number: A61K35/17 , A61K38/1774 , A61P35/00 , C07K16/2803 , C07K16/2887 , C07K16/2896 , C12N15/85 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2319/03 , C07K2319/33
Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
公开(公告)号：US12037378B2
公开(公告)日：2024-07-16
申请号：US17612993
申请日：2020-05-19
Applicant: NOVARTIS AG
Inventor： Barbara Brannetti , Dattananda Chelur , Brian Granda , Connie Hong
IPC: C07K14/705
CPC classification number: C07K14/70528
Abstract: The present disclosure provides CD2 binding molecules that specifically bind to CD2, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD2 binding molecules, and pharmaceutical compositions comprising the CD2 binding molecules and the conjugates. The disclosure further provides methods of using the CD2 binding molecules to modulate CD2 signaling in order to treat a variety of immune (e.g., autoimmune), inflammatory and proliferative disorders. The disclosure yet further provides recombinant host cells engineered to express the CD2 binding molecules and methods of producing the CD2 binding molecules by culturing the host cells under conditions in which the CD2 binding molecules are expressed.
-
18.发明申请公开(公告)号：US20190292238A1
公开(公告)日：2019-09-26
申请号：US16256731
申请日：2019-01-24
Inventor： Hans Bitter , Jennifer Mary Bordeaux , Barbara Brannetti , Jennifer Brogdon , Naveen Kumar Dakappagari , Saar Gill , Steven Highfill , Lu Huang , Carl H. June , Ju Young Kim , Ming Lei , Na Li , Andreas Loew , Elena Orlando , Marco Ruella , Thai Tran , Jimin Zhang , Li Zhou
IPC: C07K14/705 , A61K39/00 , C07K16/28 , C07K14/725 , A61K45/06
Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
-
19.发明申请公开(公告)号：US20190016797A1
公开(公告)日：2019-01-17
申请号：US16069146
申请日：2017-01-11
Applicant: Novartis AG , Universität Zürich
Inventor： Natalia Arenas-Ramirez , Iwan Beuvink , Onur Boyman , Barbara Brannetti , Andreas Katopodis , Simone Popp , Catherine Regnier , Chao Zou
Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
-
公开(公告)号：US20150218274A1
公开(公告)日：2015-08-06
申请号：US14610837
申请日：2015-01-30
Inventor： Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu
IPC: C07K16/28 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2803 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07K2299/00 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/6893
Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
Abstract translation: 公开了特异性结合TIM-3的抗体分子。 抗TIM-3抗体分子可用于治疗，预防和/或诊断免疫，癌性或感染性疾病和/或病症。
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.053 seconds)
